

Access to NTD diagnostics and WHO response

Dr Afework Tekle
Unit head, NTD

5 December 2024



World Health
Organization



Challenges with NTD diagnostics

Diagnostics will play a critical role in achieving NTD road map targets


Access challenges:

- Market for NTD diagnostics unattractive to manufacturers
- Limited availability of high sensitivity and specificity tests
- Quality of many NTD diagnostics uncertain
- Some NTD diagnostics have been discontinued
- Scarce public investments in NTD diagnostics
- Absence of coordinated global need estimates and procurement mechanisms




Landscape analysis of NTD diagnostics

Number and type of diagnostics available for NTDs.




Estimated global need and market size for NTD diagnostics.



- Of 125 diagnostics tools commercially available for NTDs included in the analysis, RDT accounts for 33%, EIA accounts for 34%, and PCR accounts for 10%.
- Demand less than 1 million units per year for each disease (except lymphatic filariasis and dengue)

WHO Diagnostics Procurement Management Process



WHO procures diagnostics for—

- Lymphatic filariasis
- Visceral leishmaniasis (for high-burden countries in Eastern Africa only)
- Human African trypanosomiasis (HAT, sleeping sickness)
- Yaws
- Chagas disease

Update on Lymphatic filariasis (LF) diagnostics (1)

Progress

- Since 2016, >5 million Filariasis Test Strips procured by WHO alone for 48 countries
- Global demand has been met through consortium (MSD-Eisai-GSK-BMGF) funds, USAID and countries
- Coordination of efforts: monthly calls with manufacturer and procuring partners to generate and update forecasts, prioritize allocation of orders


Challenges -Risks

- Potential supply gap of FTS
- **lot-to-lot variability** in Brugia RDT


Opportunities

- Validation in lab and field of new RDTs (LF Ag; Brugia Ab)
- WHO ERPD completed

Filariasis Test Strip Procurement (2)



Global procurement of Filariasis Diagnostic Tests (3)



Update on Visceral Leishmaniasis (VL) diagnostics (1)

Global forecast

- Leishmaniasis procurement steering committee meets quarterly
- Global annual forecast compiled and shared with manufacturers

Process

- WHO negotiates price and signs a long-term agreement (LTA) to include in WHO catalogue.
- All orders processed through WHO procurement unit in Kuala Lumpur



Health Products	Manufacturer	Method of Procurement
Rk39	Mologics, UK & Inbios, USA	LTA – Negotiated Price
DAT	AMC Medical Research, Netherlands Institute of Tropical Medicines, Antwerp, Belgium	RPE

ERPD

- ERPD concluded

Lab evaluations in process coordinated by WHO TDR in Kenya and Ethiopia

VL diagnostics procurement forecast (2)



Note: Procurement data from 2022 reflects the forecast for Q3 and Q4 only.

Way forward..

- Collaborative efforts towards advocacy and resource mobilization to secure access to NTD diagnostics?
- Forecasting of NTD diagnostics to be coordinated by WHO?



Thank you!

